Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19514467 | 0.76 | MEN1 (0.33) | HSP90AA1 | |
| SCHEMBL5159639 | 0.70 | APLNR (0.35) | — | |
| SCHEMBL28471871 | 0.69 | — | — | |
| SCHEMBL28009485 | 0.67 | HSP90AA1 (0.38) | HSP90AA1 | |
| SCHEMBL27847823 | 0.65 | HSP90AA1 (0.35) | HSP90AA1 | |
| SCHEMBL27938987 | 0.63 | CYP19A1 (0.32) | — | |
| SCHEMBL9182929 | 0.63 | HSP90AA1 (0.33) | HSP90AA1 | |
| SCHEMBL2363479 | 0.63 | — | — | |
| SCHEMBL3172931 | 0.63 | — | — | |
| SCHEMBL9464242 | 0.59 | HSP90AA1 (0.35) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | claimed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | claimed |
| EP-2547645-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-23 | — | — | EP | claimed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | claimed |
| WO-2011113859-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-09-22 | — | — | WO | claimed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-6953798-B1 | β-alanine derivates | CELLTECH R&D LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-5084570-A | PROCESS FOR THE PREPARATION OF 2-(2',4'-DIHYDROXYPHENYL)-4,6-DIARYL-S-TRIAZINES | CIBA-GEIGY CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0443574-A1 | Water-insoluble naphthalic acid imide dyestuffs | HOECHST MITSUBISHI KASEI CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0395938-A2 | Process for the preparation of 2-(2',4'-dihydroxyphenyl)-4,6-diaryl-s-triazines | CIBA-GEIGY AG (CH) | 1990-11-07 | — | — | EP | disclosed |
| US-4778888-A | Boron containing 1,3,5-triazines | W. R. GRACE & CO. (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0135381-B1 | REACTIVE DYES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
| US-4562251-A | Agarose derivatives of amino phenyl boronic acid | AMICON CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0135381-A1 | Reactive dyes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | HSP90AA1 2532/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | HSP90AA1 2528/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | HSP90AA1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.